Prevention of anaphylaxis related to mast cell activation syndrome with omalizumab
- 1 May 2012
- journal article
- research article
- Published by Elsevier in Annals of Allergy, Asthma & Immunology
- Vol. 108 (5) , 383-384
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Mast cell activation disease: a concise practical guide for diagnostic workup and therapeutic optionsJournal of Hematology & Oncology, 2011
- Raised tryptase without anaphylaxis or mastocytosis: heterophilic antibody interference in the serum tryptase assayClinical and Experimental Immunology, 2011
- Omalizumab Treatment of Systemic Mast Cell Activation Disease: Experiences from Four CasesInternal Medicine, 2011
- Mast cell activation syndrome: Proposed diagnostic criteriaJournal of Allergy and Clinical Immunology, 2010
- Omalizumab is effective in treating systemic mastocytosis in a nonatopic patientAllergy, 2010
- Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosisJournal of Allergy and Clinical Immunology, 2007
- Differential release of mast cell mediators and the pathogenesis of inflammationImmunological Reviews, 2007
- Anti-IgE as a mast cell–stabilizing therapeutic agentJournal of Allergy and Clinical Immunology, 2006